Loading...
•
Mar 31, 2021
Alector Q1 2021 Earnings Report
Alector reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Alector reported a collaboration revenue of $4.1 million for the quarter ended March 31, 2021, and a net loss of $52.2 million. The company's cash, cash equivalents, and marketable securities were $362.7 million as of March 31, 2021.
Enrollment ongoing for AL001 INFRONT-3 Phase 3 trial in frontotemporal dementia with a progranulin mutation.
Enrollment ongoing for AL002 INVOKE-2 Phase 2 trial in early Alzheimer’s disease patients.
Three abstracts accepted for presentation at 2021 Alzheimer’s Association International Conference (AAIC), including updated data from ongoing AL001 open-label Phase 2 study in FTD-GRN.
Alector plans to present updated data from the ongoing AL001 Phase 2 open-label study at the upcoming Alzheimer’s Association International Conference (AAIC), taking place July 26-30, 2021.
Revenue by Segment
Forward Guidance
Planning is underway to initiate first-in-human studies for AL008 and AL009, two oncology programs, in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...